Top

Sleep and Breathing

Published in:

01-08-2021 | Restless Legs Syndrome | Neurology • Original Article

Therapy satisfaction and willingness-to-pay in Polish patients with restless legs syndrome

Authors: Mariusz Sieminski, Marcelina Skrzypek-Czerko, Łukasz Chełminiak

Published in: Sleep and Breathing | Issue 2/2022

Abstract

Purpose

Restless legs syndrome (RLS) is a serious burden for patients which can be measured in economic terms by assessing the money spent on therapy and the willingness to pay. The aim of this study was to assess whether or not patients feel satisfied with the therapy relative to the money they spent on the treatment, and to assess patients’ willingness to pay for therapy that fully eliminates all RLS symptoms.

Methods

Adult subjects with RLS confirmed by actual international consensus criteria, a positive RLS-Diagnostic Index (RLS-DI) score, and clinical examinations and observations were assessed to generate a disease severity index. An original set of questions was used to collect data on patient satisfaction with therapy and their willingness to pay.

Results

Among 100 subjects, 27% were not satisfied with therapy; this subgroup was characterized by lower indices of severity of the disease. Patients spent approximately 3% of their income in treating RLS. They are willing to pay up to 8.3% of their income to eliminate symptoms.

Conclusions

The cost of RLS therapy is a significant part of patient expenditure. Nevertheless, RLS may at times remain so troublesome for patients that they are willing to spend more on therapy to eliminate symptoms.

Allen RP, Walters AS, Montplaisir J et al (2005) Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 165:1286–1292. https://doi.org/10.1001/archinte.165.11.1286CrossRefPubMed

Wesström J, Nilsson S, Sundström-Poromaa I, Ulfberg J (2010) Health-related quality of life and restless legs syndrome among women in Sweden. Psychiatry Clin Neurosci 64:574–579. https://doi.org/10.1111/j.1440-1819.2010.02116.xCrossRefPubMed

Allen RP, Picchietti DL, Garcia-Borreguero D et al (2014) Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria–history, rationale, description, and significance. Sleep Med 15:860–873. https://doi.org/10.1016/j.sleep.2014.03.025CrossRefPubMed

Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M (2011) Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev (3):CD006009. https://doi.org/10.1002/14651858.CD006009.pub2

Allen R, Chen C, Soaita A et al (2010) A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med 11:512–519. https://doi.org/10.1016/j.sleep.2010.03.003CrossRefPubMed

Trenkwalder C, Beneš H, Grote L et al (2013) Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol 12:1141–1150. https://doi.org/10.1016/S1474-4422(13)70239-4CrossRefPubMed

Bakar ZA, Fahrni ML, Khan TM (2016) Patient satisfaction and medication adherence assessment amongst patients at the diabetes medication therapy adherence clinic. Diabetes Metab Syndr 10:S139-143. https://doi.org/10.1016/j.dsx.2016.03.015CrossRefPubMed

García-Borreguero D, Williams A-M (2010) Dopaminergic augmentation of restless legs syndrome. Sleep Med Rev 14:339–346. https://doi.org/10.1016/j.smrv.2009.11.006CrossRefPubMed

Dodel R, Happe S, Peglau I et al (2010) Health economic burden of patients with restless legs syndrome in a German ambulatory setting. Pharmacoeconomics 28:381–393. https://doi.org/10.2165/11531030-000000000-00000CrossRefPubMed

10.

Reese JP, Stiasny-Kolster K, Oertel WH, Dodel RC (2007) Health-related quality of life and economic burden in patients with restless legs syndrome. Expert Rev Pharmacoecon Outcomes Res 7:503–521. https://doi.org/10.1586/14737167.7.5.503CrossRefPubMed

11.

Reinhold T, Müller-Riemenschneider F, Willich SN, Brüggenjürgen B (2009) Economic and human costs of restless legs syndrome. Pharmacoeconomics 27:267–279. https://doi.org/10.2165/00019053-200927040-00001CrossRefPubMed

12.

Lees M, Roberts G, Tabberer M et al (2008) Cost-effectiveness of licensed treatment options for restless legs syndrome in the UK and Sweden. Curr Med Res Opin 24:2919–2930. https://doi.org/10.1185/03007990802344594CrossRefPubMed

13.

Benes H, Kohnen R (2009) Validation of an algorithm for the diagnosis of restless legs syndrome: the Restless Legs Syndrome-Diagnostic Index (RLS-DI). Sleep Med 10:515–523. https://doi.org/10.1016/j.sleep.2008.06.006CrossRefPubMed

14.

Walters AS, LeBrocq C, Dhar A et al (2003) Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 4:121–132. https://doi.org/10.1016/s1389-9457(02)00258-7CrossRefPubMed

15.

Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545CrossRef

16.

Soldatos CR, Dikeos DG, Paparrigopoulos TJ (2000) Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res 48:555–560CrossRef

17.

Golicki D, Niewada M, van Hout B et al (2014) Interim EQ-5D-5L value set for Poland: first crosswalk value set in Central and Eastern Europe. Value Health Reg Issues 4:19–23. https://doi.org/10.1016/j.vhri.2014.06.001CrossRefPubMed

18.

Winkelman JW, Sethi KD, Kushida CA et al (2006) Efficacy and safety of pramipexole in restless legs syndrome. Neurology 67:1034–1039. https://doi.org/10.1212/01.wnl.0000231513.23919.a1CrossRefPubMed

19.

Högl B, Oertel WH, Stiasny-Kolster K et al (2010) Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch. BMC Neurol 10:86. https://doi.org/10.1186/1471-2377-10-86CrossRefPubMedPubMedCentral

20.

Garcia-Borreguero D, Grunstein R, Sridhar G et al (2007) A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med 8:742–752. https://doi.org/10.1016/j.sleep.2006.09.009CrossRefPubMed

21.

Hornyak M, Grossmann C, Kohnen R et al (2008) Cognitive behavioural group therapy to improve patients’ strategies for coping with restless legs syndrome: a proof-of-concept trial. J Neurol Neurosurg Psychiatry 79:823–825. https://doi.org/10.1136/jnnp.2007.138867CrossRefPubMed

22.

Bekkelund SI, Ofte HK, Alstadhaug KB (2014) Patient satisfaction with conventional, complementary, and alternative treatment for cluster headache in a Norwegian cohort. Scand J Prim Health Care 32:111–116. https://doi.org/10.3109/02813432.2014.944410CrossRefPubMedPubMedCentral

23.

Trenkwalder C, Tinelli M, Sakkas GK et al (2021) Socioeconomic impact of restless legs syndrome and inadequate restless legs syndrome management across European settings. Eur J Neurol 28:691–706. https://doi.org/10.1111/ene.14582CrossRefPubMed

24.

Goldstein E, Ho C-X, Hanna R et al (2015) Cost of care for subjective tinnitus in relation to patient satisfaction. Otolaryngol Head Neck Surg 152:518–523. https://doi.org/10.1177/0194599814566179CrossRefPubMed

25.

Stanisławska J, Agnieszka K, Głowicka-Wołoszyn R (2018) Zmiany w poziomie i strukturze wydatków polskich gospodarstw domowych o różnej sytuacji dochodowej w aspekcie zrównoważonej konsumpcji. Handel Wewnętrzny 3(374):358–370

26.

Roy AN, Madhavan SS, Lloyd A (2015) A discrete choice experiment to elicit patient willingness to pay for attributes of treatment-induced symptom relief in comorbid. Insomnia Manag Care 24:42–48PubMed

27.

Huang L, Frijters P, Dalziel K, Clarke P (2018) Life satisfaction, QALYs, and the monetary value of health. Soc Sci Med 211:131–136. https://doi.org/10.1016/j.socscimed.2018.06.009CrossRefPubMed

28.

Lampl C, Steiner TJ, Mueller T et al (2012) Will (or can) people pay for headache care in a poor country? J Headache Pain 13:67–74. https://doi.org/10.1007/s10194-011-0398-1CrossRefPubMed

29.

Bolin K, Berling P, Wasling P et al (2017) The cost-utility of sodium oxybate as narcolepsy treatment. Acta Neurol Scand 136:715–720. https://doi.org/10.1111/ane.12794CrossRefPubMed

30.

Bolin K, Niska P-Å, Pirhonen L et al (2020) The cost utility of pitolisant as narcolepsy treatment. Acta Neurol Scand 141:301–310. https://doi.org/10.1111/ane.13202CrossRefPubMed

Title: Therapy satisfaction and willingness-to-pay in Polish patients with restless legs syndrome
Authors: Mariusz Sieminski
Marcelina Skrzypek-Czerko
Łukasz Chełminiak
Publication date: 01-08-2021
Publisher: Springer International Publishing
Keyword: Restless Legs Syndrome
Published in: Sleep and Breathing / Issue 2/2022
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI: https://doi.org/10.1007/s11325-021-02440-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Therapy satisfaction and willingness-to-pay in Polish patients with restless legs syndrome

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2022

High flow nasal cannula therapy for obstructive sleep apnea in adults

Changes in platelet count and coagulation parameters in children with obstructive sleep apnea

High-flow nasal cannula compared with continuous positive airway pressure in the treatment of obstructive sleep apnea

Risk factors for non-positional obstructive sleep apnea–hypopnea syndrome

Factors affecting compliance with positive airway pressure therapy in obstructive sleep apnea

Application of machine learning analysis based on diffusion tensor imaging to identify REM sleep behavior disorder

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page